...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of experimental & clinical cancer research : >A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy
【24h】

A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy

机译：对胶质母细胞瘤的聚（I：C）和Poly-ICLC的系统综述：协调解锁免疫疗法的佐剂

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Immunotherapy is currently under intensive investigation as a potential breakthrough treatment option for glioblastoma. Given the anatomical and immunological complexities surrounding glioblastoma, lymphocytes that infiltrate the brain to develop durable immunity with memory will be key. Polyinosinic:polycytidylic acid, or poly(I:C), and its derivative poly-ICLC could serve as a priming or boosting therapy to unleash lymphocytes and other factors in the (immuno)therapeutic armory against glioblastoma. Here, we present a systematic review on the effects and efficacy of poly(I:C)/poly-ICLC for glioblastoma treatment, ranging from preclinical work on cellular and murine glioblastoma models to reported and ongoing clinical studies. MEDLINE was searched until 15 May 2021 to identify preclinical (glioblastoma cells, murine models) and clinical studies that investigated poly(I:C) or poly-ICLC in glioblastoma. A systematic review approach was conducted according to PRISMA guidelines. ClinicalTrials.gov was queried for ongoing clinical studies. Direct pro-tumorigenic effects of poly(I:C) on glioblastoma cells have not been described. On the contrary, poly(I:C) changes the immunological profile of glioblastoma cells and can also kill them directly. In murine glioblastoma models, poly(I:C) has shown therapeutic relevance as an adjuvant therapy to several treatment modalities, including vaccination and immune checkpoint blockade. Clinically, mostly as an adjuvant to dendritic cell or peptide vaccines, poly-ICLC has been demonstrated to be safe and capable of eliciting immunological activity to boost therapeutic responses. Poly-ICLC could be a valuable tool to enhance immunotherapeutic approaches for glioblastoma. We conclude by proposing several promising combination strategies that might advance glioblastoma immunotherapy and discuss key pre-clinical aspects to improve clinical translation.
机译：免疫疗法目前正在密集调查，作为胶质母细胞瘤的潜在突破性治疗选择。鉴于胶质母细胞瘤的解剖和免疫综合性，浸润淋巴细胞，渗透到脑部以延长内存耐用的免疫力。多胞苷：聚环烷酸，或聚（I：C），其衍生物多ICLC可以用作释放或促进淋巴细胞和（免疫）治疗尸体中的其他因素对抗胶质母细胞瘤的灌注疗法。在这里，我们对Poly（I：C）/ Poly-ICLC用于胶质母细胞瘤治疗的效果和功效的系统审查，从临床前工作术中报告和正在进行的临床研究。在2021年5月15日之前搜索了Medline，以鉴定临床前（胶质母细胞，鼠模型）和临床研究，并在胶质母细胞瘤中调查聚（I：C）或Poly-ICLC。根据Prisma指南进行了系统审查方法。 ClinicalTrial.gov被询问持续临床研究。未描述Poly（I：C）对胶质母细胞瘤细胞的直接促致致致致致致致致致致致瘤瘤的作用。相反，聚（i：c）改变胶质母细胞瘤细胞的免疫学特征，也可以直接杀死它们。在鼠胶质细胞瘤模型中，Poly（I：C）表现出治疗相关性与若干治疗方式的辅助疗法，包括疫苗接种和免疫检查点阻断。临床上，主要是作为树突细胞或肽疫苗的佐剂，已经证明了Poly-ICLC是安全的并且能够引发免疫活性以提高治疗反应。 Poly-ICLC可以是增强胶质母细胞瘤免疫治疗方法的有价值的工具。我们通过提出一些可能提高胶质母细胞瘤免疫疗法的有前途的组合策略，并讨论关键前方面以改善临床翻译的关键前提。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号